Pharming (PHAR) Non-Current Assets (2019 - 2026)

Pharming's Non-Current Assets history runs 8 years deep, the most recent figure standing at $193.9 million for Q1 2026.

• Quarterly Non-Current Assets rose 2.53% year-over-year to $193.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.9 million (up 2.53% YoY) and the FY2025 annual result came in at $200.5 million, up 64.96% from the prior year.
• Non-Current Assets was $193.9 million for Q1 2026 at Pharming, down from $200.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $200.5 million in Q4 2025 and bottomed at $130275.0 in Q3 2022.
• A 5-year average of $150.7 million and a median of $146.5 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets sank 99.92% — and 2023, when it surged 110995.76%.
• Pharming's Non-Current Assets stood at $148.3 million in 2022, then fell by 1.2% to $146.5 million in 2023, then retreated by 17.04% to $121.5 million in 2024, then surged by 64.96% to $200.5 million in 2025, then decreased by 3.31% to $193.9 million in 2026.
• Business Quant data shows PHAR's Non-Current Assets at $193.9 million in Q1 2026, $200.5 million in Q4 2025, and $196.2 million in Q3 2025.